FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the method of treating or preventing cancers, which are associated with the expression of CLDN18.2, it can be used in medicine. Method is a combination therapy comprising administration of antibodies to CLDN18.2 and cytotoxic and/or cytotoxic agents.
EFFECT: invention allows to effectively treat or prevent diseases, which are associated with the cells expressing CLDN18.2, including cancer diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer, gall bladder cancer and their metastases.
39 cl, 26 dwg, 2 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
| ANTIBODY TO CLDN18.2 AND ITS USE | 2018 |
|
RU2797709C2 |
